1. World Health Organization. Cancer pain relief. 2nd edition, with a guide to opioid availability. Geneva 1996. 2. Ventafridda V. et al.: A validation study of the WHO method for cancer pain relief. Cancer, 1987, 59:951-956. 3. Zech D.F. et al.: Validation of World Health Organization guidelines for cancer pain relief: A 10-year prospective study. Pain, 1995, 63:65-76. 4. Portenoy R.K. et al.: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain, 1990, 43:273-286. 5. Rawal N.: Opiods in acute pain. In: red. Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 247-270. 6. Gutstein H.B., Akil H.: Opioid analgesics. W: Goodman and Gilman. The pharmaceutical basis of therapeutics. Mc Graw Hill Medical Publishing Division 10^th Ed. 569-611. 7.Darland T. et al.: Orphanon FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci, 1998, 21 (5):215-221. 8.Henderson G., McKnight A.T.: The orphan opioid receptor and its endogenous ligand- niciceptin/orphanin FQ. Trends Pharmacol Sci., 1997, 18:293-300. 9. Raynor K. et al.: Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol., 1994, 45:330-334. 10. Ross F., Smith M.: The intrinsic antyinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain, 1997, 73:151-157. 11. Rothman R.: Buprenorphine: a rewiev of binding literature. In: Cowan A., Lewis J. (red.): Buprenorphine: combatting drug abuse with unique opioid. Wiley-Liss, New York, 151-163. 12.Budd K.: Buprenorphine: a review. Evidence Based Medicine in Practice (April 2002), Hayward Medical Communications, Newmarket. 13. Hill R.G.: Multiple opioid receptors and their ligands. Frontiers of Pain, 1992, 4:1-4. 14. Corbett A.D. et al.: Selectivity of ligands for opioid receptors. In: Herz A. (red.): Opioids. Springer-Verlag, London 1993, 657-672. 15.Twycross R. et al.: Analgesics. In: Palliative Care Formulary, Radcliffe Medical Press, 2002, 129-202. 16. Woolf C.J., Mannion R.J.: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999, 353:1959-64. 17. Heinricher M.M., Morgan M.M.: Supraspinal Mechanisms of opioid analgesia. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 46-69. 18. Stein C. et al.: Peripheral opioid analgesia: mechanisms and clinical implications. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 96-108. 19. Woolf C., Bromley L.: Pre-emptive analgesia by opioids. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 212-233. 20. Sivilotti L.G. et al.: Morphine selectively depresses the slowest, NMDA-independent component of C-fibre evoked synaptic activity in the rat spinal cord in vitro. Eur. J. Neurosci., 1995, 7:12-18. 21.Dickenson A.H.: Where and how do opioids act? In: Gebhart G.F., Hammond D.L., Jensen T.S.: Proceedings of the 7^th World Congress on Pain. Progress in pain research and management. Vol. 2. IASP Press. Seattle, 1994, 525-552. 22. Mao J. et al.: Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain, 1995, 62:259-274. 23. Wiesenfeld-Hallin Z., Xiao-Jun Xu: Opioid-nonopioid interaction. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 131-143. 24. Cesselin F. et al.: Spinal mechanisms of opioid analgesia. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 70-95. 25. Duttaroy A., Yoburn B.C.: The effect of intrinsic efficacy on opioid tolerance. Anesthesiology, 1995, 82:1226-1236. 26. Sosnowski M., Yaksh T.L.: Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anaesthesiology, 1990, 73:1141-1147. 27. Sanford T.J. et al.: A comparison of morphine, fentanyl, and sufentanil anaesthesia for cardiac surgery: Induction, emergence, and extubation. Anesth. Analg., 1986, 65:159-166. 28. Bilsky E.J. et al.: Competitive and non-competitive NMDA antagonists block the developement of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain, 1996, 68:229-237. 29. Mather L.E., Smith M.: Clinical Pharmacology and Adverse Effects . In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 188-211. 30. Kujawska-Tenner J. i wsp.: Zwalczanie bólów nowotworowych. MZOS, Warszawa 1994. 31. Leppert W. et al.: Tramadol and cancer pain. European Journal of Palliative Care, 2002, 9 (2):49-51. 32. Raffa R.B. et al.: Opioid and non-opioid components indepedently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. Journal of Pharmacology and Therapeutics, 1992, 260:275-285. 33. Poulsen L. et al.: The hypoalgesic effect of tramadol in relation to CYP2D6. Clinical Pharmacology and Therapeutics, 1996, 60:636-644. 34. Lurcott G. et al.: The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesthesia Progress, 1999, 45:154-156. 35. Fromm M. et al.: Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans. Clinical Pharmacology and Therapeutics, 1995, 58:374-382. 36. Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer, 2001, 84:587-593. 37. Boerner U. et al.: The metabolism of morphine and heroin in man. Drug metabolism reviews, 1975, 4(1):39-57. 38. Mazoit J-X. et al.: Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesthesia and Analgesia, 1987, 66:293-298. 39. Sandouk P. et al.: Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine. European Journal of Drug Metabolism and Pharmacology, 1991, 16 (suppl. 3):166-171. 40. Corrupt P. et al.: Morphine-6-glucuronide and morphine-3-glucuronide as a molecular chameleons with unexpected lipophylicity. J. Med. Chem. 1991, 34:1272-1275. 41. Hanna M.H. et al.: Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br. J. Anaesth., 1990, 64:547-550. 42.Woolf T. et al.: Morphine nad morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain, 1995, 62:147-154. 43. Portenoy R.K. et al.: Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology, 1991, 41:1457-61. 44. McQuay H.J. et al.: Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin. Pharmacol. Ther., 1990, 48:236-244. 45. Säwe J. et al.: Kinetics of morphine in patients with renal failure. Lancet, 1985, 211. 46. Peterson G.M. et al.: Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur. J. Clin. Parmacol., 1990, 38:121-124. 47. Portenoy R.K. et al.: Plasma morphine and morphine-6-glucuronide during morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain, 1991, 47:13-19. 48. Faura C.C. et al.: Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain, 1998, 74 (1):43-53. 49. Houde R.W. et al.: Clinical measurement of pain. In: de Stevens G. (eds.): Analgesics. Academic Press, NY, 1965, 75-122. 50. Twycross R.G.: Oral morphine. In: Twycross R.G.: Pain relief in advanced cancer. Churchill Livingstone, 1994, 307-332. 51. Continous Cancer Pain. Durogesic. Fentanyl Transdermal System. Monograph. CMC International Inc., USA 2001. 52. Donner B. et al.: Long-term treatment of cancer pain with transdermal fentanyl. J. Pain. Symptom. Manage., 1998, 15 (3):168-175. 53. Fine P.G. et al.: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain, 1991, 45:149-153. 54. Lewis J.: Clinical pharmacology of buprenorphine in relation to its use as an analgesic. In: Cowan A., Lewis J. (red.): Buprenorphine: combatting drug abuse with unique opioid. Wiley-Liss, New York, 151-163. 55. Radbruch L.: Transtec- Buprenorfina TDS. X Congress on Pain. San Diego, 2002. 56. Pausawasdi S. et al.: The effect of buprenorphine and morphine on intraluminal pressure of the common bile duct. Journal of Medical Association of Thailand, 1985, 76:329-333. 57. Gorman A. et al.: The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters, 1997, 223:5-8. 58. Codd E. et al.: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in nociception. Journal of Pharmacology and Experimental Therapeutics, 1995, 274:1263-1270. 59. Morley J., Makin M.: The use of methadone in cancer pain poorly responsive to other opioids. Pain Rewievs, 1998, 5:51-58. 60. Krajnik M., Żylicz Z.: Metadon w leczeniu bólu nowotworowego. Polska Medycyna Paliatywna, 2002, Nr1, Tom 1:15-22. 61. Nilsson M.I. et al.: Clinical pharmacokinetics of methadone. Acta Anaesthesiol. Scand., 1982, 26 (supl.74):66-69. 62. Farrel A., Rich A.: Analgesic use in patients with renal failure. Eur. J. Palliat. Care, 2000, 7:201-205. 63. Mancini I.L. et al.: Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J. Palliat. Med., 2000, 3:49-56. 64. Heiskanen T., Kalso E.: Controlled-release oxycodone and morphine in cancer related pain. Pain, 1997, 73:37-45. 65. Heiskanen T. et al.: Effects of blocking CYP2D6 on oxycodone. Clinical Pharmacology and Therapeutics, 1998, 64:603-611. 66.Anderson R. et al.: Accuracy in analgesic dosing: Conversion dilemmas. J.Pain Symptom Manage, 2001, 21:397-406. 67. de Stoutz N.D. et al.: Opioid rotation for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage, 1995, 10:378-384. 68. Sjögren P. et al.: Disappearance of morphine-induced hyperalgesia after discontinuing of substitution morphine with other opioid agonists. Pain, 1994, 59:313-316. 69. Vigano A. et al.: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain, 1996, 67:115-119. 70. Ripamonti C. et al.: Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? Journal of Clinical Oncology, 1998, 16 (10): 3216-3221. 71. Osborne R.J. et al.: Morphine and metabolite behaviour after different routes of administrationof the importance of the active metabolite morphine-6-glucutronide. Clin. Pharmacol. Ther., 1990, 47:12-19. 72. Van Dongen R.T.M. et al.: Morphine and morphine glucuronide concentrations in plasma and CSF during long-term administration of oral morphine. Br. J. Pharmacol., 1994, 38:271-273. 73. Gouke C.R. et al.: Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine resistat pain. 1994, 56:145. 74. Tiseo P.J. et al.: Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain, 1995, 61:47-54. 75. Sjögren P. et al.: Myoclonic spasm during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol, Scand., 1993, 37:780-782. 76. Bruera E., Pereira J.: Neuropsychiatric toxicity of opioids. In: Jensen T.S., Turner J.A., Wiesenfeld-Hallin Z.: Proceedings of the 8^th World Congress on Pain. Progress in pain research and management. Vol.8. IASP Press. Seattle, 1997, 717-738. 77. Krajnik M., Żylicz Z.: Topical opioids. fact or fiction? Progress in Pall. Med., 1997, 5 (3):101-106. 78. Portenoy R.K. et al.: Breakthrough pain: definition, prevalence and characteristics. Pain, 1990, 41:273-281. 79. Portenoy R.K. et al.: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain, 1999, 81:129-134. 80. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer, 2002, 95 (1):203-208. 81. The essential adjuvant analgesics for neuropathic pain. Cancer Pain Release, 2002, Vol.15, No2:1-4. 82. Oshima E. et al.: Continuous subcutaneous injection of ketamine for cancer pain. Can. J. Anaesth., 1990, 37:385-92. 83. Mercadante S. et al.: Long-term ketamine subcutaneous contineous infusion in neuropathic cancer pain. J. Pain Symptom Manage, 1995, 10 (7):564-568. 84. Broadley K.E. et al.: Ketamine injection used orally. Palliative Medicine, 1996, 10:247-250. 85. Mercadante S. etal.: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. Journal of Pain and Symptom Management, 2000, 20 (4):246-252. 86. Łuczak J. et al.: The role of ketamine, an NMDA receptor antagonist, in the management of pain. Progress in Palliative Care, 1995, 3:127-134. 87. Kotlińska-Lemieszek A. et al.: Miejsce ketaminy w leczeniu bólów nowotworowych. Wyniki 12-letnich obserwacji. II Międzynarodowe Sympozjum. Postępy w leczeniu bólu. Zakopane, 25-28 września 2002. Ból, 2002, 3, 3:43.